Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors.

Martina S J McDermott,Neil A O'Brien, Benjamin Hoffstrom,KeWei Gong,Ming Lu, Jun Zhang,Tong Luo, Min Liang, Weiping Jia, Jenny Hong, Kevin Chau, Simon Davenport, Bin Xie,Michael F Press,Richard Panayiotou, Abram Handly-Santana,Joan S Brugge, Leonard Presta,John Glaspy,Dennis J Slamon

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 1|浏览42

暂无评分

摘要

We report the development of a novel antibody-drug conjugate, CLDN6-23-ADC, that selectively targets CLDN6, a potential onco-fetal-antigen which is highly expressed in ovarian and endometrial cancers. CLDN6-23-ADC exhibits robust tumor regressions in mouse models of human ovarian and endometrial cancers and is currently undergoing Phase I study.

查看译文

关键词

solid tumors,antibody–drug

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要